Pneumocystis Pneumonia: Signs, Symptoms and Pathophysiology

Daniel Mathew*
Department of Pulmonology, Medical University - Sofia, Bulgaria

Commentary

Received date: 17/10/2021
Accepted date: 22/10/2021
Published date: 27/10/2021

*For Correspondence
Daniel Mathew
Department of Pulmonology, Medical University - Sofia, Bulgaria

Keywords: Pneumonia, Pulmonology
E-mail: danielmathew@edu.bg

Symptoms
During the early onset of the infection, you may not have symptoms, or they could be mild. They may include:

• Fever (It's usually low if you have HIV and higher if you don't.)
• Dry cough or wheezing
• Shortness of breath
• Fatigue
• Chest pain or tightness when you breathe
• Chills
• Weight loss

Symptoms gradually come on slowly and over several weeks, in people who have HIV. In ones whose immune systems are vulnerable for any other reason, they tend to start over a few days. PCP generally seen in people who've had undergone an organ transplant, who have HIV, blood cancers, or who take certain drugs for autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Pneumocystis Pneumonia in People with HIV
Since 1980s, even before there was medicine to treat HIV, about three-quarters of individuals who had AIDS got PCP. Antiretroviral therapies (ART) now helps people with HIV from getting AIDS, and now no longer suffer from PCP. But in people having AIDS, it's still the most common opportunistic infection – a disease that happens more often or is worse in people with weak immune systems.

You're most likely to get PCP when your CD4 cell count (a type of white blood cell) is less than two hundred. People who have HIV and get PCP are eight times more likely to need to stay in the hospital than those who have PCP but not HIV. Even with treatment, PCP can be deadly for people who have AIDS.
Pathophysiology

The chance of PCP will increase while CD4-positive T-cell ranges are much less than 2 hundred cells/μL. In those immunosuppressed individuals, the manifestations of the infection are particularly variable. The disorder attacks the interstitial, fibrous tissue of the lungs, with marked thickening of the alveolar septa and alveoli, leading to massive hypoxia, which may be deadly if now no longer dealt with aggressively. In this situation, lactate dehydrogenase tiers boom and fueloline alternate is compromised. Oxygen is much less capable of diffuse into the blood, main to hypoxia, which alongside excessive arterial carbon dioxide (CO2) levels, stimulates hyperventilatory effort, thereby causing dyspnea (breathlessness).